Skip to main content

Table 1 Baseline demographic characteristics and clinical outcomes for each biomaker

From: Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Parameter (no.of patients, %) EGFR mutation pTyr1068 pTyr1173
   + - p + - p + - p
Total case 92(44.9) 113(55.1) - 164(80.0) 41(20.0) - 95(57.6) 70(42.4) -
Age <75 85(45.9) 100(54.1) 0.479 148(80.0) 37(20.0) 0.598 86(58.5) 61(41.5) 0.615
  ≥75 7(35.0) 13(65.0)   16(80.0) 4(20.0)   9(50.0) 9(50.0)  
Gender Male 40(40.4) 59(59.6) 0.135 77(77.8) 22(22.2) 0.276 48(57.8) 35(42.2) 0.536
  Female 52(49.1) 54(50.9)   87(82.1) 19(17.9)   47(57.3) 35(42.7)  
Somking history Never* 59(50.9) 57(49.1) 0.024 94(81.0) 22(19.0) 0.394 49(51.6) 46(48.4) 0.102
  Ever 26(35.1) 48(64.9)   58(78.4) 16(21.6)   38(63.3) 22(36.7)  
  Unknown 7(46.7) 8(53.3)   12(80) 3(20)   8(80) 2(20)  
Histology ADC 76(45.0) 93(55.0) 0.541 134(79.3) 35(20.7) 0.414 75(55.1) 61(44.9) 0.152
  Non-ADC 16(45.7) 19(54.3)   29(82.9) 6(17.1)   19(67.9) 9(32.1)  
  Unknown 0 1(100)   1(100) 0   1(100) 0  
Disease stage III 20(57.1) 15(42.9) 0.078 26(74.3) 9(25.7) 0.249 18(60) 12(40) 0.841
  IV 71(42.3) 97(57.7)   136(81.0) 32(19.0)   77(57.5) 57(42.5)  
  Unknown 1(50) 1(50)   2(100) 0   0 2(100)  
TKIs theraphy Total 89(45.9) 105(54.1) - 154(79.4) 40(20.6) - 90(57.7) 66(42.3) -
Line First 22(27.4) 32(30.5) 0.623 42(27.3) 12(3.00) 0.843 48(57.8) 35(42.2) 0.365
  Second 67(72.6) 73(69.5)   112(72.7) 28(70.0)   47(57.3) 35(42.7)  
Best response CR 0(0) 0(0) <0.001 0(0) 0(0) <0.001 0(0) 0(0) 0.028
  PR 43(50.0) 17(17.0)   58(39.5) 2(5.1)   25(27.8) 25(37.9)  
  SD 29(33.7) 42(42.0)   57(38.8) 14(35.9)   33(36.7) 30(45.5)  
  PD 14(15.7) 41(38.3)   32(20.8) 23(56.1)   32(35.6) 11(16.7)  
ORR CR + PR 43(50.0) 17(17.0) <0.001 58(39.5) 2(5.1) <0.001 25(27.8) 25(37.9) 0.123
DCR CR + PR + SD 72(83.7) 59(59.0) <0.001 115(78.2) 16(41.0) <0.001 48(57.8) 35(42.2) 0.007
  PD 14(16.3) 41(41)   112(72.7) 28(70.0)   47(57.3) 35(42.7)  
PFS (months) Median 8.8 2.1 0.024 7 1.2 <0.001 4.8 7.2 0.016
  95%CI 6.11-11.42 0.89-3.24   5.14-8.86 0.96-1.51   2.37-7.23 3.69-11.85  
  1. Abbreviations: EGFR, epidermal growth factor receptor; pTyr, phophorylated tyrosine; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; *Never-smoker refers to patients had never smoked in their lifetime.